Home Stock

Stock Research: Cipla

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Cipla

NSEI:CIPLA INE059A01026
91
  • Value
    96
  • Growth
    49
  • Safety
    Safety
    67
  • Combined
    98
  • Sentiment
    70
  • 360° View
    360° View
    91
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Cipla Limited is a global pharmaceutical company that develops, manufactures, and markets a wide range of branded and generic formulations and APIs. The company operates in the pharmaceuticals and new ventures segments. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective, and central nervous system (CNS) areas. Its main geographical segments include India, the United States, South Africa, and the Rest of the World. In the last fiscal year, the company had a market cap of $13,867 million, profits of $2,035 million, and revenue of $3,224 million with 30313 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 91 (better than 91% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Cipla are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Cipla. The consolidated Value Rank has an attractive rank of 67, which means that the share price of Cipla is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 67% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 96. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 70. But the consolidated Growth Rank has a low rank of 49, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 51 of its competitors have better growth. ...read more

more
Country India
Industry Pharmaceuticals
Size Large
Website cipla.com
Index
Low Emissions
Good Governace Growth Markets
Human Rights
Low Waste
Recycling
CNX Nifty 50
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
67 61 61 65
Growth
49 53 51 53
Safety
Safety
96 89 77 57
Sentiment
70 89 47 98
360° View
360° View
91 95 76 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
52 54 59 74
Opinions Change
50 95 50 69
Pro Holdings
n/a 80 67 80
Market Pulse
65 78 21 73
Sentiment
70 89 47 98
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
67 61 61 65
Growth
49 53 51 53
Safety Safety
96 89 77 57
Combined
98 89 79 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
67 60 64 65
Price vs. Earnings (P/E)
56 48 50 65
Price vs. Book (P/B)
57 52 60 64
Dividend Yield
51 48 34 34
Value
67 61 61 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
38 37 34 23
Profit Growth
17 49 73 58
Capital Growth
71 45 57 75
Stock Returns
75 61 49 45
Growth
49 53 51 53
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
85 82 74 54
Refinancing
82 62 72 78
Liquidity
86 68 60 39
Safety Safety
96 89 77 57

Similar Stocks

Discover high‑ranked alternatives to Cipla and broaden your portfolio horizons.

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

Bosch

BSE:500530
Country: India
Industry: Auto Parts & Equipment
Size: Medium
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis
OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.